Simcere Pharmaceutical Group (SEHK:2096) - Stock Price, News & Analysis

2096 Stock Overview

2096 fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	1/6
Past Performance	5/6
Financial Health	6/6
Dividends	1/6

Rewards

Trading at 60.4% below our estimate of its fair value

Revenue is forecast to grow 13.93% per year

Earnings grew by 210.3% over the past year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 55.1%

Risk Analysis

Earnings are forecast to decline by an average of 24.1% per year for the next 3 years

High level of non-cash earnings

Simcere Pharmaceutical Group Limited Competitors

United Laboratories International Holdings

SEHK:3933

HK$15.1b

Grand Pharmaceutical Group

SEHK:512

HK$15.2b

China Traditional Chinese Medicine Holdings

SEHK:570

HK$19.2b

SSY Group

SEHK:2005

HK$12.8b

Price History & Performance

Summary of all time highs, changes and price drops for Simcere Pharmaceutical Group
Historical stock prices
Current Share Price	HK$6.85
52 Week High	HK$14.70
52 Week Low	HK$5.83
Beta	0.51
1 Month Change	7.03%
3 Month Change	-8.79%
1 Year Change	-21.45%
3 Year Change	-33.11%
5 Year Change	n/a
Change since IPO	-37.61%

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28

Recent updates

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27

Simcere Pharmaceutical Group Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Mar 27

Should You Be Adding Simcere Pharmaceutical Group (HKG:2096) To Your Watchlist Today?

Mar 21

Does Simcere Pharmaceutical Group (HKG:2096) Deserve A Spot On Your Watchlist?

Nov 24

Why Simcere Pharmaceutical Group's (HKG:2096) Soft Earnings Are Just The Beginning Of Its Problems

May 03

Simcere Pharmaceutical Group Limited (HKG:2096) Not Flying Under The Radar

Apr 21

Shareholder Returns

	2096	HK Pharmaceuticals	HK Market
7D	7.9%	10.5%	0.9%
1Y	-21.4%	-3.5%	11.5%

Return vs Industry: 2096 underperformed the Hong Kong Pharmaceuticals industry which returned -3.5% over the past year.

Return vs Market: 2096 underperformed the Hong Kong Market which returned 11.5% over the past year.

Price Volatility

Is 2096's price volatile compared to industry and market?
2096 volatility
2096 Average Weekly Movement	5.2%
Pharmaceuticals Industry Average Movement	5.6%
Market Average Movement	6.5%
10% most volatile stocks in HK Market	14.3%
10% least volatile stocks in HK Market	3.2%

Stable Share Price: 2096 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 2096's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1995	7,661	Jinsheng Ren	https://www.simcere.com

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets.

Simcere Pharmaceutical Group Limited Fundamentals Summary

How do Simcere Pharmaceutical Group's earnings and revenue compare to its market cap?
2096 fundamental statistics
Market Cap	HK$17.96b
Earnings (TTM)	HK$3.36b
Revenue (TTM)	HK$7.48b

5.3x

P/E Ratio

2.4x

P/S Ratio

Is 2096 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
2096 income statement (TTM)
Revenue	CN¥7.00b
Cost of Revenue	CN¥1.58b
Gross Profit	CN¥5.42b
Other Expenses	CN¥2.27b
Earnings	CN¥3.14b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	1.20
Gross Margin	77.38%
Net Profit Margin	44.92%
Debt/Equity Ratio	10.0%

How did 2096 perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

13%

Payout Ratio

2096 Stock Overview

Rewards

Risk Analysis

Simcere Pharmaceutical Group Limited Competitors

SEHK:3933

HK$15.1b

SEHK:512

HK$15.2b

SEHK:570

HK$19.2b

SEHK:2005

HK$12.8b

Price History & Performance

Recent News & Updates

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

Co-Founder recently bought HK$1.2m worth of stock

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Consensus revenue estimates fall by 22%

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Recent updates

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

Co-Founder recently bought HK$1.2m worth of stock

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Consensus revenue estimates fall by 22%

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold HK$710k worth of stock

New minor risk - Insider selling

Co-Founder recently sold HK$2.3m worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Co-Founder recently bought HK$1.5m worth of stock

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Co-Founder recently sold HK$3.1m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Consensus revenue estimates fall by 13%

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Now 23% undervalued

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration

Now 24% undervalued

Co-Founder recently bought HK$7.9m worth of stock

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023

Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration

Now 20% undervalued

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study

Insufficient new directors

Simcere Pharmaceutical Group Limited Announces Executive Changes

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.024 (vs CN¥0.21 in 1H 2021)

Consensus EPS estimates fall by 20%

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021)

Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes

Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China

Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022

Upcoming dividend of CN¥0.15 per share

Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2021

Simcere Pharmaceutical Group Limited Announces Appointment of Tang Renhong as Co-Chief Executive Officer